ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 130 filers reported holding ASCENDIS PHARMA A/S in Q3 2019. The put-call ratio across all filers is 0.17 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $51,765,000 | -14.4% | 350,000 | -34.8% | 2.96% | -17.9% |
| Q1 2020 | $60,439,000 | -34.5% | 536,710 | -19.0% | 3.61% | -23.1% |
| Q4 2019 | $92,237,000 | +47.3% | 663,000 | +2.0% | 4.69% | +42.6% |
| Q3 2019 | $62,608,000 | -16.4% | 650,000 | 0.0% | 3.29% | -5.6% |
| Q2 2019 | $74,848,000 | +47.9% | 650,000 | +51.2% | 3.49% | +38.3% |
| Q1 2019 | $50,611,000 | – | 430,000 | – | 2.52% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 133,691 | $13,805,000 | 36.44% |
| RA Capital Management | 7,567,900 | $781,462,000 | 16.67% |
| Q Global Advisors, LLC | 145,209 | $16,699,000 | 11.49% |
| BERYLSON CAPITAL PARTNERS, LLC | 51,000 | $5,266,000 | 8.70% |
| Spyglass Capital Management LLC | 949,915 | $98,088,000 | 6.94% |
| Paradigm Biocapital Advisors LP | 497,347 | $51,356,000 | 6.85% |
| Avoro Capital Advisors LLC | 2,850,000 | $294,291,000 | 5.44% |
| Deep Track Capital, LP | 1,000,000 | $103,260,000 | 4.73% |
| Finepoint Capital LP | 123,400 | $12,742,000 | 4.19% |
| Deep Track Capital, LP | 800,000 | $82,608,000 | 3.78% |